Anthelmintic reclassification causes concern for vets
16 March 2017
BVA has expressed concern following the announcement by the Veterinary Medicines Directorate (VMD) regarding the reclassification of Zolvix, an anthelmintic for sheep, from POM-V to a POM-VPS.
BVA President Gudrun Ravetz said:
"We know that resistance to anthelmintics is increasing
in grazing animals and needs to be addressed if the livestock industry is to
avoid a potentially disastrous situation of being unable to tackle parasites.
The reclassification of Zolvix from POM-V to POM-VPS is in direct
opposition to the trend in Europe, where we are seeing increased control over
dispensing of anthelmintics in species where resistance is a serious threat to
animal welfare and profitable production; we're extremely concerned that we
might start seeing resistance develop in group 4 as a result.
“BVA believes that prescribing of anthelmintics requires
a level of control best provided by a veterinary surgeon who has the animals
under his/her care, and is based on a sound clinical diagnosis, in order to
protect animal welfare and safeguard the efficacy of these products for the
Further information on BVA's policy on anthelmintics can be found here: www.bva.co.uk/news-campaigns-and-policy/policy/medicines/anthelmintics.